Skip to main content

Table 1 Baseline clinical characteristics

From: Concomitant renal insufficiency and diabetes mellitus as prognostic factors for acute myocardial infarction

  Group I (n = 5700) Group II (n = 1730) Group III (n = 1431) Group IV (n = 1044) p Value
      Overall Linear†
Age (years) 61 ± 13 62 ± 11 71 ± 11 70 ± 9‡§ < 0.001  
Age groups (years)      < 0.001 < 0.001
   < 65 2671(47%) 706(41%) 231(16%) 136(13%)   
   65-74 2165(38%) 781(45%) 598(42%) 586(56%)   
   ≥ 75 864(15%) 243(14%) 602(42%) 322(31%)   
Male (%) 4411(77) 1222(71) 812(57) 534 (51)ठ< 0.001 < 0.001
Body weight (kg) 65 ± 12 66 ± 12 61 ± 12 62 ± 11 0.095  
Body mass index (kg/m2) 24 ± 3 25 ± 4 23 ± 3 24 ± 3§ 0.483  
HR(beats/minute) 76 ± 20 80 ± 20 79 ± 31 83 ± 26‡§ < 0.001  
Systolic blood pressure(mm Hg) 130 ± 27 130 ± 28 121 ± 35 127 ± 34 < 0.001  
Diastolic blood pressure(mm Hg) 80 ± 19 79 ± 16 74 ± 21 76 ± 35 < 0.001  
Current smoker (%) 3690(65) 990(58) 660(46) 380(37)ठ< 0.001 < 0.001
Treatment of Diabetes mellitus       
   No treatment (%) 5700(100) 260(15.2) 1431(100) 65(7)   
   Insulin treatment (%)   101(5.8)   160(15)   
   Oral hypoglycemic agents (%)   1369(79)   819(78)   
Previous hypertension (%) 2168(38) 987(57) 863(60) 772(74)ठ< 0.001 < 0.001
Previous dyslipidemia (%) 497(9) 212(12) 118(8) 133(13)§ < 0.001 0.001
Family history of CAD (%) 446(8) 118(7) 63(4) 43(4) < 0.001 < 0.001
Previous CAD (%) 684(12) 311(18) 293(21) 273(26)ठ< 0.001 < 0.001
Killip class > I (%) 1099(20) 423 (25) 603 (43) 508 (50)ठ< 0.001 < 0.001
LDL-C (mg/dl) 120 ± 40 114 ± 38 112 ± 43 110 ± 52 < 0.001  
NT-proBNP (pg/ml) 323
(81, 1151)
468
(123, 1577)
1750 (338, 6804) 3522 (877, 10894) < 0.001  
hs-CRP 0.64 (0.17, 3.53) 0.92 (0.23, 4.15) 1.46 (0.30, 6.59) 2.19 (0.36, 9.70) < 0.001  
LVEF (%) 53 ± 12 51 ± 12 49 ± 14 46 ± 14‡§ < 0.001  
STEMI (%) 3619(64) 1009(58) 908(63) 518(50)‡§ < 0.001  
Non-STEMI (%) 2083(37) 722(42) 524(37) 526(50)‡§ < 0.001  
Kidney function       
   Serum Creatinine (mg/dL) 0.92 ± 0.19 0.91 ± 0.19 2.08 ± 3.58 2.38 ± 3.44‡§ < 0.001  
   Estimated GFR* (ml/min/1.73 m2) 88.9 ± 39.2 87.5 ± 32.9 44.7 ± 14.2 39.0 ± 15.9‡§ < 0.001  
Medications (%)       
   Aspirin 5616 (99) 1706 (99) 1381 (97) 1009(97) < 0.001 < 0.001
   Clopidogrel 5523(97) 1675(97) 1340(94) 968(93) < 0.001 < 0.001
   Beta blocker 4295 (76) 1337 (78) 908 (64) 694 (67) < 0.001 < 0.001
   CCB 707(12) 215(13) 205(14) 208(20)‡§ < 0.001 < 0.001
   Statin 4274 (75) 1295 (75) 906 (64) 667 (64) < 0.001 < 0.001
   ACE inhibitor 4191 (74) 1294 (75) 891 (63) 629 (60) < 0.001 < 0.001
   ARB 656 (12) 249 (14) 235 (17) 213 (21)‡§ < 0.001 < 0.001
  1. Data are presented as mean ± SD or number of patients (percentage). Not normally distributed variables were described as median (25th, 75th percentile). Group I, estimated GFR ≥ 60(ml/min/1.73 m2) without DM; Group II, estimated GFR ≥ 60 with DM; Group III, estimated GFR < 60 without DM; Group IV, estimated GFR < 60 with DM.
  2. Abbreviations: HR, heart rate; CAD, coronary arterial disease; LDL-C, low-density lipoprotein cholesterol; NT-proBNP, N-terminal pro-brain natriuretic peptide; hs-CRP, high-sensitivity C-Reactive Protein; LVEF, left ventricular ejection fraction; STEMI, ST-segment elevation acute myocardial infarction; GFR, Glomerular filtration rate; CCB, calcium channel blocker; ACE, angiotensin converting enzyme; ARB, angiotensin II receptor blockers.
  3. *On the basis of abbreviated MDRD (Modification of Diet in Renal Disease) study equation.
  4. †Statistical significance for linear-by-linear association between categorical variables calculated using chi-square-test for trend.
  5. p < 0.05 Compared with Group I.
  6. p < 0.05 Compared with Group II.
  7. § p < 0.05 Compared with Group III.